Making the stock market and investing with confidence is a common goal for new and old investors.
While you may have an investment style that you rely on, the Zacks-style score makes it easier to find quality stocks. These are complementary indicators that score inventory based on value, growth, and/or momentum characteristics.
For momentum investors, up and down trend precedents for stock prices or earnings outlooks, so they want a score of zero with momentum style. This score can use factors such as price changes over the week and monthly percentage changes in income estimates to determine a good time to build a position in stocks.
Headquartered in San Francisco, California, Hims & Hers Health, Inc. is a consumer-centric health and wellness platform that redefines healthcare with personalized solutions and seamless digital access. Founded in 2017, the company specializes in subscription-based services and retail partnerships that meet a variety of health needs in key treatment categories. The company operates under dual revenue streams – online subscription and wholesale retail.
Hims is the Zacks No. 1 (strongly bought) stock with B-type B and VGM scores B, with B-shares down 8.5% in the past week and up 13.4% in the past four weeks. Hims has also earned 134% in the past year. Looking at the volume, an average of 33,722,048 shares have been exchanged in the last 20 trading days.
Momentum investors should not only pay attention to price changes; positive income also plays a crucial role. An analyst revised its earnings estimates in the past 60 days of fiscal 2025. Zacks consensus estimates increased by $0.02 to $0.75 per share. Hims' average income surprise was 19.6%.
With strong revenue growth, good Zacks rankings, and top dynamics and VGM style scores, investors should consider adding his portfolio to their portfolio.
Want the latest tips for Zacks Investment Research? Today, you can download 7 best stocks in the next 30 days. Click to get this free report
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report
This article was originally published on Zacks Investment Research (Zacks.com).
Zacks Investment Research